SecBot SecBot
DEFA14A ·Filed Apr 7, 2026

CNMD

CONMED Corp
NEUTRAL
Impact 3/10
Horizonimmediate Processed6mo ago SEC0001140361-26-013497
Proxy solicitation materials
Actionable Insight • Neutral

This is a standard proxy filing. The recent appointment of an interim CFO may indicate internal changes, but the proxy statement itself does not contain new financial data or strategic shifts. Traders should monitor for further developments related to the CFO role.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final: all horizons settled through T+60d
CNMD ▼ -2.06% at T+60d
NEUTRAL call -2.06% · α vs SPY -15.33% · entry $34.54 → $33.83
Entry = T+0 close
Apr 7, 2026
via day close
T+1d
+5.94%
call +5.94% · α +3.40%
$36.59
settled 7mo ago
T+5d
+15.03%
call +15.03% · α +9.70%
$39.73
settled 7mo ago
T+20d
+3.88%
call +3.88% · α -5.90%
$35.88
settled 6mo ago
T+60d
-2.06%
call -2.06% · α -15.33%
$33.83
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

This DEFA14A filing is a definitive proxy statement for CONMED Corp's 2026 annual meeting, detailing proposals for the election of seven directors, an advisory vote on executive compensation, and the ratification of the independent auditor. It follows a recent 8-K filing announcing an interim CFO appointment, suggesting ongoing board-level changes. The filing is routine and does not contain material financial information.

Key Financial Metrics

Vote
director election
Meeting
2026-05-18
Seats Contested
7

Key Facts

  • The filing is a definitive proxy statement for CONMED Corp's annual meeting on May 18, 2026.
  • Proposals include the election of seven directors, an advisory vote on executive compensation, and the ratification of PricewaterhouseCoopers LLP as the independent auditor.
  • A recent 8-K filing announced the appointment of Andrew Moller as Interim Principal Financial Officer, effective March 15, 2026.

Financial Impact

No material financial impact.

Risk Factors

  • The appointment of an interim CFO may signal potential instability or transition in financial leadership.
  • No immediate financial risk is indicated by this filing.

Market Snapshot

Exchange
NYSE
Sector
Electromedical & Electrotherapeutic Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001140361-26-013497
Document: 0001140361-26-013497-index-headers.html0001140361-26-013497
Document: 0001140361-26-013497-index.html0001140361-26-013497
Document: 0001140361-26-013497.txt0001140361-26-013497
4 reports for CNMD
Performance horizon
Filters
Rows
Reports for CNMD, sortable and filterable
TypeNow
Jun 17, 2026
18w ago
8-K
NEUTRAL ★ 3/10
$32.58 $45.01▲ +38.15%▲ +37.62%$47.20 (+44.87%)
Jun 1, 2026
21w ago
8-K
MIXED ★ 6/10
$34.65 $32.73▼ −5.54%▼ −4.24%$47.20 (+36.22%)
May 20, 2026
22w ago
8-K
NEUTRAL ★ 3/10
$37.01 $32.58▼ −11.97%▼ −12.71%$47.20 (+27.53%)
Apr 7, 2026
29w ago
DEFA14A
NEUTRAL ★ 3/10
$34.54 $35.88▲ +3.88%▼ −5.90%$47.20 (+36.65%)
Showing 4 of 4

US Market Status

Market Closed · Opens in 4h 10m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 7, 2026